As promised in our previous research report on Syneron (TICKER: ELOS), we have completed our research on the potential of its next block buster product: Ultrashape fat reduction device. Over the past month we have interviewed leading physicians in the aesthetics and fat reduction space, industry specific research firms, regulatory experts including FDA submissions professionals, and patients.
Having learned about the product, its history, and Syneron's excellent FDA track record, we have strong conviction that Syneron's Ultrashape will receive FDA clearance during 2014. Due to the combination of FDA approval, the US market demand for additional FDA approved fat reduction devices and the ease of use of Ultrashape for both physicians and patients, we firmly believe that Syneron's hidden...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|